Lecanemab, a drug designed to slow the progression of early stage Alzheimer's will not be available to patients in Sweden for ...

The study showed significant reductions in serum TTR levels in subjects after a single dose, with sustained effects over time ...

These bacteria have evolved the ability to resist treatment with antibiotics, and it's making them more deadly and harder to ...

Princeton: Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

Despite their promise, these therapies have faced significant regulatory and access challenges. In July, the European ...

Healthcare products provider RHEA Generics is committed to promoting affordable healthcare by offering generic medications ...

(RTTNews) - Janssen-Cilag International NV, a Johnson & Johnson company (JNJ), Monday said that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended ...

A new study reveals that more than half of cancer drugs approved by the FDA under accelerated pathways are not authorized in ...

Lecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of ...

Patients with MSI-high/dMMR advanced colorectal cancers had a 79 percent lower risk of disease progression or death on Opdivo-Yervoy compared to chemo.

The US Food and Drug Administration approved Augtyro in 2023 for the treatment of ROS1-positive advanced NSCLC. Earlier this year, the FDA also approved the drug for adult and pediatric patients 12 ...

The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...